AstraZeneca has signed a deal with Chinese pharmaceutical company CanSino Biologics to develop potential messenger RNA vaccines, as the company expands its work to include the technology first proven in the Covid-19 pandemic.Shares in CanSino rose more than 25 per cent on Wednesday after the company announced the agreement to provide manufacturing services for the Anglo Swedish drugmaker. The companies did not disclose the value of the deal.
阿斯利康(AstraZeneca)與中國制藥公司康希諾生物(CanSino Biologics)簽署了一項協議，將開發潛在的mRNA疫苗。目前，阿斯利康正在擴大其研發范圍，將這種在新冠疫情中首次得到驗證的技術納入其中。
您已閱讀13%（555字），剩余87%（3580字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。